MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).
Details are listed below:
Webcast details
AUSTRALIA PARTICIPANTS:
Date: | Thursday, 25 July 2024 | ||
Time: | 8:30 a.m. AEST (Sydney/Melbourne) |
UNITED STATES PARTICIPANTS:
Date: | Wednesday, 24 July 2024 | ||
Time: | 3:30 p.m. Pacific Time | ||
6:30 p.m. Eastern Time |
Register for the Zoom webcast: https://mstfinancial-au.zoom.us/webinar/register/WN_8zfACjD8TqO7SsMcAyxzkg
Registration is required and dial in details will be sent directly upon registration.
Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
This email address is being protected from spambots. You need JavaScript enabled to view it.
+61 450 648 064
U.S.
Remy Bernarda
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 (415) 203-6386
Last Trade: | US$1.24 |
Daily Change: | -0.02 -1.59 |
Daily Volume: | 3,106 |
Market Cap: | US$10.990M |
July 17, 2024 June 12, 2024 May 29, 2024 April 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB